

RxInsights[®]

CEBT

Benefit by Trust

Jul 2022 - May 2023

Prescription Benefit Review

 **CVS**Health[®]



Today—Your prescription benefit review

Based on our discussions, as your account team, we are working together toward the following goals:

Effectively Manage Cost / Trend
Create the best Member Experience
Collaborative Strategic Planning

In this rapidly changing market, we know that continuous monitoring of the health care market - including trend drivers - and the ability to adapt quickly is essential to help ensure the success of your benefit strategy. Our consultative services play a major role in support of your strategic objectives for managing pharmacy and total health care trend. The insights and recommendations provided within this report will help ensure you have the right solutions in place to control costs and maintain high client/employee satisfaction. We look forward to a meaningful discussion today. Thank you for your time.

Sincerely,

Kyle Smith, Lead Director

Richard Edwards, Executive Director

Kurt Neuenfeld, Clinical Manager

Amanda Massey, Lead Director, Government Affairs

In this RxInsights® review we'll:

- Assess how your plan is performing.
- Provide relevant benchmarks to put your numbers in context.
- Discuss how your plan was affected by specific trend drivers.
- Identify anticipated trend drivers.
- Make recommendations that will help you reduce trend and achieve your benefit plan goals.

Legislative Landscape

Colorado Legislative Update

Political Overview:

- Democrats control the House, Senate, & Governor’s Office
- Saving people money on healthcare has been a political priority for Governor Polis throughout his first term
- The Legislature elected in 2022 is much more progressive than the previous legislature and wants more government intervention in healthcare – including for employers

2023 PBM Legislation

Bill	What it does	Markets impacted
PBM Regulation (HB 1201)	Prohibits spread pricing for fully insured plans and requires PBMs or their carrier affiliates to provide disclosures/reporting to their clients on drug costs.	Fully insured ERISA/non-ERISA self funded opt-in
Cost sharing/copay coupons (SB 195)	Requires a carrier or PBM to include any amount paid by the covered person, or by another person on behalf of the covered person when calculating an out-of-pocket maximum or cost sharing requirement (relates to copay coupons from pharmaceutical manufacturers).	Fully insured
PBM Registration (HB 1227)	Requires PBMs to register with and pay a registration fee to the Division of Insurance, while also requiring insurers to pay a fee to the DOI with a list of the PBMs they use for prescription drug benefits administration. The fees are to be used by the DOI to enforce current statutory provisions on PBMs.	All PBMs must register (regardless of whether they service fully insured or self-funded clients)

Clinical Landscape & Program Savings Summary

Pipeline and Notable Approvals

Active drug pipeline remains a key challenge for payors seeking to balance coverage and cost

2023-2025 anticipated pipeline¹

606 new drugs

211 supplemental specialty indications

34 gene therapy products

30 biosimilar approvals and **41** launches

Specialty

Alzheimer's Disease

- Leqembi (lecanemab) – Approved 1/2023
- Donanemab – Q2 2023
- Gantenerumab – Q3 2023

Tzield - Approved 12/2022 to delay the onset of Stage 3 Type 1 diabetes (T1D) in adults and patients aged 8 years and older with Stage 2 T1D

Myasthenia Gravis

- Efgartigimod – Q1 2023
- Rozanolixizumab – Q2 2023
- Zilucoplan – Q4 2023

Hemophilia

- **Altuviiiio** (Efanesoctocog alfa) – Q1 2023 – Once weekly
- Concizumab – Q2 2023

Non-Specialty

Opvee (nalmephephene) - The emergency treatment of known or suspected opioid overdose (2q2023)

Neffy (epinephrine nasal spray) – Treatment of allergic reactions, including anaphylaxis (Q2 2023)

RSV Vaccine for Adults

- **Abrysvo** (RSVpreF) – Q2 2023
- **Arexvy** (GSK3844766A) – Q2 2023
- mRNA-1345 -2024



Biosimilar Landscape

Disrupting the drug market by increasing competition, biosimilars present an opportunity to drive down costs



Biosimilars by numbers

40

biosimilars approved¹

26

launched, covering 9 drugs²

\$75B

projected spend by 2030³

Autoimmune (AI) Pipeline

AI typically represents 40-50% of specialty drug spend. CEBT AI spend was 52%.

Two-Year Biosimilar Outlook⁴:

- Actemra (2)
- Humira (10)- Amjevita launched 1/31/23
- Stelara (5)
- Simponi (1)



Basic Terminology

Biosimilar- Biologic that is highly similar and has no clinically meaningful difference from an existing FDA-approved reference product

Interchangeable Biosimilar- Biosimilar that meets additional requirements by the FDA and may be substituted for a reference product without prescriber intervention when state law allows. It is expected to produce the same clinical result as the reference product in any given patient

Reference Product - A single biological product, already FDA approved by the FDA, against which a proposed biosimilar product is compared



Formulary Considerations

A robust biosimilar pipeline presents an opportunity to significantly reduce drug costs. Because each biosimilar will differ from others as well as the reference product, we have a unique framework in place to evaluate these newly available products.

Our key considerations are:

- Lowest Net Cost strategy
- Formulation and interchangeability
- Product attributes and availability
- Adequate supply for our members and patients; and
- Member experience including patient support

Gene Therapy Awareness



Gene therapies insert DNA containing a functioning gene into a cell, to replace a faulty or missing one, to correct the effects of a disease-causing mutation.

Notable Approvals

Zolgensma - Costs more than **\$2.1M** per pediatric patient with spinal muscular atrophy (SMA)¹

Luxturna - Costs as much as **\$425K** (per eye) in patients with biallelic RPE65 mutation-associated retinal dystrophy²

Zynteglo - Costs as much as **\$2.8M** per patient with β -thalassemia who require regular red blood cell (RBC) transfusions³

Skysona - Costs as much as **\$3.0M** per patient with cerebral adrenoleukodystrophy (CALD)⁴

Hemophilia

Hemgenix (etranacogene dezaparvovec);

- Indication: Hemophilia B
- Launched: December 2022
- Population Impact: 2,600 adults; \$3.5M (one-time replacement or incremental spend)

Roctavian (valoctocogene roxaparvovec)

- Indication: Hemophilia A
- Anticipated Approval: TBD
- Population Impact: 7500 adults; \$1.5M to \$3.5 million (one-time replacement or incremental spend)

Place in Therapy:

- Gene therapies are processed through the medical benefit
- Provides hemophilia patients with years of functioning factor levels and improved quality of life, while minimizing bleeding episodes
- There is unknown durability and long-term safety data and patients with inhibitors will not be candidates
- The pipeline continues to be robust with factor, non-factor, and other gene therapies

Pipeline

Gene therapies are very costly treatments but can be a potential one-time curative treatment and a replacement for a lifetime of drug therapy.

The FDA expects to approve up to **20** gene and cell therapies per year by **2025**⁵

\$15 billion to over **\$45 billion** estimated 5-year cost impact to the healthcare system of the most significant monogenetic therapies in the pipeline

Other disease states with promising gene therapy options:

- Duchenne's Muscular Dystrophy
- Sickle Cell Anemia
- High-Risk Non-Muscle-Invasive Bladder Cancer

Program savings summary

Total Savings: ~\$8.6M

Clinical Solution	Intervention Summary	Total Count	Total Gross Savings	Total Net Savings	Total Member Savings
Dose Optimization	Optimized Claims	559	\$16,182		
Drug Savings Review	Drug Savings Review Edits			\$539,969	
Pharmacy Advisor Support Gaps in Care Outcomes*	Members With Gap Interventions Eligible For Resolution	40	\$807		
	Members with Resolved Gaps	2			
Prior Authorization	Episodes Resulting in PA Approval	1,011			
	Episodes Resulting in PA Denial + Alternative Fill	9			
	Episodes Resulting in PA Denial	180			
	Episodes Resulting in PA Admin Denial	65	\$322,010	\$255,788	
	Episodes Resulting in No PA Requested + Alternative Fill	186			
	Episodes Resulting in No PA Requested	1,587			
Quantity Limits	Episodes Resulting in Full Quantity Filled	120			
	Episodes Resulting in Reduced Quantity Filled	929			
	Episodes Resulting in Target Drug Not Filled	510	\$234,482	\$189,798	
	Episodes Resulting in Full Quantity Filled with Delay	362			
Safety and Monitoring Solutions	Members Targeted	49	\$21,451	\$19,566	
	Case Referrals	1			

*APR 2022 – MAR 2023 Experience Period

Program savings summary

Clinical Solution	Intervention Summary	Total Count	Total Gross Savings	Total Net Savings	Total Member Savings
Specialty Guideline Management	Episodes Resulting in PA Approval	631	\$4,051,972	\$3,936,108	
	Episodes Resulting in PA Denial	138			
	Episodes Resulting in PA Admin Denial	61			
	Episodes Resulting in No PA Requested	190			
Specialty Quantity Limits	Episodes Resulting in Full Quantity Filled	3	\$3,433,982	\$3,337,833	
	Episodes Resulting in Reduced Quantity Filled	55			
	Episodes Resulting in Target Drug Not Filled	8			
	Episodes Resulting in Full Quantity Filled with Delay	2			
Step with PA	Episodes Resulting in PA Approval	171	\$19,010	\$15,180	
	Episodes Resulting in PA Denial + Alternative Fill	4			
	Episodes Resulting in PA Denial	42			
	Episodes Resulting in PA Admin Denial	61			
	Episodes Resulting in No PA Requested + Alternative Fill	12			
	Episodes Resulting in No PA Requested	10			


* Savings represent Total Healthcare Savings

*APR 2022 – MAR 2023 Experience Period

Utilization & Trend

Experience Period: July 2022 – May 2023

Demonstrating overall value of PBM management




* Cost prior to managed program savings, AWP discounts, and rebate impact.
 ** Any outcomes savings presented for Specialty Guideline Management, Quantity Limits, Prior Authorization, or Step Therapy is for the period Jul-2022 through Apr-2023.
 † Rebates represent client share of invoiced rebates as of report run date of 06-21-2023 and may not reconcile with rebate guarantees or rebates paid to date. Rebates included for this time period: 2022Q3 - 2023Q1.



Working together to deliver best in class trend

(with impact of rebates)

Contribution to Trend



Key metrics at a glance

Eligibility	Jul-May 22	% Change	Jul-May 23	Employer†	Peer*
Average Eligible Members Per Month	30,275	7.6%	32,571		
Average Utilizers as % of Members	30.2%	-1.1%	29.8%	35.1%	42.3%
Average Member Age	37	-0.3%	37	36	40
Cost with Rebates**					
Total Gross Cost	\$41,650,315	17.1%	\$48,769,846		
Gross Cost w/ Rebates**	\$31,865,382	15.5%	\$36,797,658		
Total Net Cost w/ Rebates**	\$28,698,570	16.0%	\$33,289,097		
Gross Cost PMPM	\$125.07	8.8%	\$136.12		
Gross Cost w/ Rebates** PMPM	\$95.68	7.3%	\$102.71		
Net Cost w/ Rebates** PMPM	\$86.18	7.8%	\$92.91		
% Total Member Cost Share	7.6%	-5.4%	7.2%	8.7%	7.6%
% Non-Specialty Member Cost Share	15.7%	-6.2%	14.7%	13.0%	12.0%
Drug Mix					
% Single Source Brands	14.0%	-4.9%	13.3%	15.1%	14.8%
% Multi Source Brands	2.7%	-12.0%	2.4%	1.6%	1.4%
Generic Dispensing Rate	83.3%	1.2%	84.3%	83.3%	83.7%
Generic Substitution Rate	96.8%	0.4%	97.2%	98.1%	98.3%
Utilization					
Total Prescriptions	209,737	6.9%	224,118		
% Retail Prescriptions	73.2%	-0.6%	72.8%	80.2%	89.1%
% Mail Prescriptions	4.5%	-3.2%	4.3%	5.1%	4.4%
% Retail 90 Prescriptions	22.3%	2.6%	22.9%	NA	NA
Days' Supply PMPM	26.06	0.5%	26.18	35.09	47.96
Specialty					
Specialty Total Gross Cost	\$22,510,140	17.5%	\$26,453,418		
Specialty Avg. Utilizers as % of Members	0.9%	4.8%	1.0%	1.1%	1.3%
Specialty Gross Cost PMPM	\$67.59	9.2%	\$73.83	\$80.79	\$101.54
Specialty % of Total Gross Cost	54.0%	0.4%	54.2%	48.8%	46.6%
Specialty % of Total Prescriptions	1.8%	5.3%	1.9%	1.5%	1.4%
% Specialty Member Cost Share	0.7%	16.1%	0.9%	4.1%	2.5%


*Peer: Government

** Rebates represent client share of invoiced rebates (less: point of sale rebates) as of report run date of 06-21-2023 and may not reconcile with rebate guarantees or rebates paid to date.


Rebates included for this time period: 2022Q3 - 2023Q1. Prior period rebates include the same number of quarters as current period.

†Employer information is based on the most recent year ending Mar 31, 2023.

Your gross trend



Your specialty and non-specialty trend




Your top specialty classes by contribution to trend

Key metrics

Specialty prescriptions represented **54.2%** of total gross cost and comprised **1.9%** of all prescriptions.

Newly launched medications contributed **1.0%** to specialty trend.

Price inflation contributed **5.4%** to specialty trend.



5.3%

Overall specialty utilization increase compared to prior period



The top three (3) classes with the greatest contribution to specialty drug utilization trend are:
Rheumatoid Arthritis
Atopic Dermatitis
Asthma

Your top 5 contributing specialty classes

Specialty Class	Top Drug Contributors	Gross Cost	Utilizers	Gross Cost PMPM	Contribution to Gross Trend
Rheumatoid Arthritis	Enbrel, Rinvoq	\$5,178,937	110	\$14.45 \$12.39	1.7%
Oncology	Verzenio, Lumakras	\$3,227,573	72	\$9.01 \$18.05	1.0%
Ulcerative Colitis	Humira, Stelara	\$926,131	13	\$2.58 \$2.97	0.7%
Atopic Dermatitis	Dupixent	\$721,115	33	\$2.01 \$3.57	0.7%
Inflammatory Bowel Disease	Humira, Cimzia	\$377,038	6	\$1.05 \$0.66	0.6%

Peer:Government

This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

Your top non-specialty classes by contribution to trend

Key metrics

Non-specialty prescriptions represented

45.8%

of total gross cost and comprised


98.1%

of all prescriptions.

Newly launched medications contributed

1.4%

to non-specialty trend.



0.4%

Overall non-specialty utilization increase compared to prior period



The top three (3) classes with the greatest contribution to non-specialty drug utilization trend are:
Antidiabetics
Adhd/Anti-Narcolepsy/Anti-Obesity/Anorexiant
Antidepressants

Your top 5 contributing non-specialty classes

Non-Specialty Class	Top Drug Contributors	Gross Cost	Utilizers	Gross Cost PMPM	Contribution to Gross Trend
Antidiabetics	Ozempic, Trulicity	\$6,882,711	1,698	\$19.21 \$40.32	3.3%
Migraine Products	Nurtec, Qulipta	\$1,525,314	856	\$4.26 \$4.85	1.0%
Antiasthmatic And Bronchodilator Agents	Trelegy Ellipta, Advair Diskus	\$2,074,355	3,240	\$5.79 \$6.82	0.2%
Antihyperlipidemics	Rosuvastatin Calcium, Praluent	\$589,033	2,595	\$1.64 \$3.64	0.2%
Adhd/Anti-Narcolepsy/Anti-Obesity/Anorexiant	vyvanse, Amphetamine/Dextroamphetamine	\$1,306,129	1,419	\$3.65 \$10.10	0.2%

Peer:Government

This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

Prudent Rx & Digital Innovation

You and your members benefit with the PrudentRx difference



More accurate savings

Incremental savings considers previous benefit design in calculating the client net cost

\$0 participating member OOP

for every specialty fill*

Coinsurance set at 30%

across the program drug list**

Seamless member experience, high-touch member engagement – integrated effort to help ensure members are informed and enrolled

Powered by PrudentRx

Independent third-party vendor, 30+combined years experience in health care and specialty.

Expertise in plan design, specialty pharmacy and copay card programs.

Certified minority owned business.

*Participating members enrolled in an HDHP with an HSA must fully satisfy their deductible before they are eligible for a final \$0 OOP cost under the program, unless the member has been prescribed a medication that qualifies as “preventive care” under the IRC, which is administered and enforced by the IRS. Members may still utilize available copay assistance while in their deductible phase but must satisfy their deductible before the Plan is able to pick up any of the costs on the members’ behalf. **Due to limitations that exist within various external pharmacy systems, implementing the PrudentRx solution on HDHPs with HSAs will be limited to only those medications included on the client’s specialty drug list and dispensed by CVS Specialty and will not include limited distribution no access drugs.

Reduce specialty spend with the PrudentRx solution

Up to
22%
gross savings*

~2,400
clients†

-13.1%
average negative specialty
trend for clients with the PrudentRx
solution

\$0
participating
member out-
of-pocket cost**

99.9%
of members
remain opted in

\$106M
member
savings

“ We have only heard positive feedback
from members about this program.”

— Senior Manager of Healthcare Solutions, Large Retail
Company

“ I thought the savings estimate seemed
too good to be true. **The actual savings
were even greater than expected.** ”

— SENIOR DIRECTOR OF BENEFITS, NJ HEALTH CARE COMPANY

*Incremental savings may be less for high-deductible health plans (HDHP) than non-HDHPs. A savings analysis can be made available upon request. **Participating members enrolled in a HDHP with a health savings account (HSA) must fully satisfy their deductible before they are eligible for a final \$0 out-of-pocket cost under the program, unless the member has been prescribed a medication that qualifies as “preventive care” under the Internal Revenue Code (IRC), which is administered and enforced by the Internal Revenue Service (IRS). Members may still utilize available copay assistance while in their deductible phase but must satisfy their deductible before the Plan is able to pick up any of the costs on the members’ behalf. †As of January 2023.



72.5%
net promoter
score

We're integrating the digital experience across CVS Health platforms

Bringing it all together so members get access to care when, how and where they need it

- Single sign-on for fast and easy access
- Important information that helps members make decisions about their health
- Valuable features that help them manage their condition and medications



Thank you

Appendix

Key insights and drivers of trend with rebate impact

Key metrics	CEBT All	% Change from Prior	Peer
Average Eligible Members	32,571	7.6%	
Total Rx	224,118	6.9%	
Gross Cost Before Rebates	\$48,769,846	17.1%	
Rebates**	\$11,972,187	22.4%	
Specialty Gross Cost	\$26,453,418	17.5%	
Specialty as a % of Total Gross Cost	54.2%	0.4%	46.6%
Generic Dispensing Rate	84.3%	1.2%	83.7%


Trend drivers	Total	Specialty
	CEBT All	CEBT All
Price Inflation	3.2%	5.4%
Utilization	0.5%	5.3%
Drug Mix	4.9%	-1.6%

Your top contributors to trend	Gross Cost	Contribution to	
		CEBT All	Peer
Overall Class			
Antidiabetics	\$6,882,711	3.3%	4.2%
Dermatologicals	\$5,902,606	2.2%	2.3%
Analgesics - Anti-Inflammatory	\$9,196,142	2.1%	1.0%
Specialty			
Rheumatoid Arthritis	\$5,178,937	1.7%	0.4%
Oncology	\$3,227,573	1.0%	1.0%
Ulcerative Colitis	\$926,131	0.7%	0.3%

Peer:Government


** Rebates represent client share of invoiced rebates (less: point of sale rebates) as of report run date of 06-21-2023 and may not reconcile with rebate guarantees or rebates paid to date. Rebates included for this time period: 2022Q3 - 2023Q1. Prior period rebates include the same number of quarters as current period.

Gross Trend with Rebates




Utilization by Channel

- CVS Specialty
- Mail
- Maintenance Choice
- Retail/Other Acute
- Retail/Other Maintenance



Your Gross Cost PMPM



Specialty pharmacy trend, cost & utilization metrics

Price inflation

5.4%

Utilization

5.3%

Drug mix

-1.6%

Specialty
gross trend

9.2%

Your specialty utilization metrics

	Jul-May 22	% Change	Jul-May 23	Jul-May 23	Jul-May 23
Specialty Prescriptions	3,721	12.5%	4,186	Employer	Peer*
Specialty Rx as % of Total Prescriptions	1.8%	5.3%	1.9%	1.5%	1.4%
% CVS Specialty Pharmacy Prescriptions	95.4%	0.2%	95.6%		
Specialty Utilizers	483	16.6%	563		
Specialty Utilizers as % of Utilizers	2.1%	9.4%	2.3%		
Average Age Per Specialty Utilizer	45.6	1.1%	46.1		

Your specialty cost metrics

	Jul-May 22	% Change	Jul-May 23	Jul-May 23	Jul-May 23
Specialty Gross Cost	\$22,510,140	17.5%	\$26,453,418	Employer	Peer*
Specialty % of Total Gross Cost	54.0%	0.4%	54.2%	48.8%	46.6%
Specialty Net Cost	\$22,343,455	17.4%	\$26,225,981		
Specialty % of Total Net Cost	58.1%	-0.2%	57.9%	51.2%	49.1%
Specialty Member Cost	\$166,685	36.4%	\$227,436		
% Specialty Member Cost Share	0.7%	16.1%	0.9%	4.1%	2.5%
Gross Cost Per Specialty Utilizer	\$46,605	0.8%	\$46,987		
Specialty Avg. Utilizers as % of Members	0.9%	4.8%	1.0%	1.1%	1.3%

*Peer: Government

Your top 25 specialty drugs

By gross cost

BOB Rank†	Prior Rank	Current Rank	Drug Name	Specialty Class	Total Gross Cost	% of Specialty		Gross		
						Gross Cost	Utilizers	Total Rx	Cost Per Rx	Gross Cost Per Days' Supply
1	1	1	Humira	Rheumatoid Arthritis	\$2,748,371	10.39%	47	370	\$7,428.03	\$269.87
2	3	2	Stelara	Crohn's Disease	\$1,394,664	5.27%	13	56	\$24,904.71	\$483.25
243	0	3	Kovaltry	Hemophilia	\$1,008,593	3.81%	2	21	\$48,028.22	\$1,600.94
4	5	4	Humira	Crohn's Disease	\$739,397	2.80%	11	89	\$8,307.83	\$283.95
5	17	5	Dupixent	Atopic Dermatitis	\$721,115	2.73%	33	202	\$3,569.87	\$123.90
30	6	6	Hemlibra	Hemophilia	\$711,778	2.69%	1	11	\$64,707.13	\$2,310.97
7	10	7	Enbrel	Rheumatoid Arthritis	\$697,373	2.64%	20	106	\$6,578.99	\$234.96
3	15	8	Skyrizi	Psoriasis	\$656,768	2.48%	12	36	\$18,243.55	\$229.96
10	7	9	Taltz	Psoriasis	\$628,081	2.37%	11	82	\$7,659.53	\$249.24
26	21	10	Verzenio	Oncology	\$567,086	2.14%	4	42	\$13,502.05	\$482.22
25	13	11	Xeljanz	Rheumatoid Arthritis	\$521,732	1.97%	12	102	\$5,115.02	\$170.50
27	12	12	Xolair	Asthma	\$519,800	1.96%	29	194	\$2,679.38	\$95.69
23	19	13	Humira	Ankylosing Spondylitis	\$514,674	1.95%	9	81	\$6,353.99	\$226.93
219	2	14	Kogenate Fs	Hemophilia	\$477,511	1.81%	2	8	\$59,688.91	\$2,231.36
71	8	15	Enbrel	Ankylosing Spondylitis	\$459,501	1.74%	9	71	\$6,471.85	\$231.14
19	16	16	Cosentyx	Psoriatic Arthritis	\$401,402	1.52%	7	57	\$7,042.13	\$251.50
17	23	17	Otezla	Psoriasis	\$395,243	1.49%	14	92	\$4,296.11	\$143.20
69	14	18	Rebif	Multiple Sclerosis	\$382,068	1.44%	4	42	\$9,096.85	\$324.89
22	35	19	Rinvoq	Rheumatoid Arthritis	\$380,455	1.44%	9	67	\$5,678.44	\$189.28
16	31	20	Humira	Ulcerative Colitis	\$346,808	1.31%	5	47	\$7,378.89	\$263.53
46	61	21	Humira	Inflammatory Bowel Disease	\$336,717	1.27%	5	25	\$13,468.68	\$481.02
12	29	22	Revlimid	Oncology	\$330,357	1.25%	7	21	\$15,731.29	\$589.92
35	22	23	Orencia	Rheumatoid Arthritis	\$327,637	1.24%	9	66	\$4,964.20	\$177.29
39	59	24	Kesimpta	Multiple Sclerosis	\$326,472	1.23%	5	43	\$7,592.37	\$262.02
28	20	25	Aubaqio	Multiple Sclerosis	\$317,628	1.20%	4	38	\$8,358.63	\$278.62
Total Top Gross Specialty Drugs										\$15,911,230
Total Top Gross Specialty Drugs/Overall Biotech Specialty Drugs										60.15%

†Employer information is based on the most recent year ending Mar 31, 2023.

This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

Digital solutions help improve clinical outcomes, reduce medication waste and lower health care costs

Key metrics

523 CVS Specialty Utilizers

54 Average Attempted Communications

33 Average Successful Communications

499 (95.4% of CVS Specialty Utilizers) Opt-in Digital

393 (78.8% of Opt-In Messaging Utilizers) Filled

Digital Breakdown Campaign type

Clinical Messages	1,526	Operational Messages	14,444
Side Effects	428	Order Management	13,115
Adherence	372	Insurance and Billing	1,329
Condition Management	326		
Adherence Monitoring	288		
Symptom and Condition Monitoring	106		
Adherence Management	4		
Safety	2		

Top 5 drug classes

Specialty Class	Population		Messaging Method		
	CVS Specialty Utilizers	Opt-in Digital Messaging	Text	Email	Both
Rheumatoid Arthritis	104	96.2%	1,899	1,990	147
Oncology	47	97.9%	454	422	108
Hemophilia	5	40.0%	15	7	0
Crohns Disease	26	100.0%	322	359	14
Psoriasis	47	95.7%	575	575	79

*Average Communications per member are across all communication channels (digital and telephonic)

Improving access and engaging members with Specialty Connect™

Key metrics

2.7%

of

523

total Specialty Pharmacy Utilizers have initiated their Specialty Rx from one of our CVS Retail Pharmacies

5.3%

of

3,994

total Specialty Rx's were picked up from one of our CVS Retail Pharmacies

Delivery choices for specialty utilizers



Top 9 specialty drug classes

Specialty Class	Total Specialty Pharmacy Utilizers	% Specialty Connect Utilizers	Specialty Connect Utilizers	Total Rx	Delivery Choice			
					Retail	Office	Home	Other
Rheumatoid Arthritis	104	2.9%	3	808	40	0	692	76
Asthma	51	0.0%	0	334	1	153	169	11
Oncology	47	2.1%	1	293	15	0	248	30
Psoriasis	47	6.4%	3	248	28	1	218	1
Atopic Dermatitis	31	0.0%	0	196	8	2	146	40
Human Immunodeficiency Virus	31	0.0%	0	274	22	0	247	5
Transplant	31	0.0%	0	339	17	0	322	0
Psoriatic Arthritis	28	0.0%	0	223	19	0	202	2
Multiple Sclerosis	27	14.8%	4	243	17	0	209	17
Other	143	2.1%	3	1,036	44	22	859	111
Overall Total	523	2.7%	14	3,994	211	178	3,312	293

Your adherence metrics

Helping patients with 3+ chronic conditions become adherent can increase savings 7 fold.

% optimal ¹ adherence by most common conditions	CEBT All Current Period	CEBT All Prior Period	Age Adjusted ^{**} Peer*	Age-Adjusted ^{**} Employer
Diabetes Total number of adherent utilizers 931	72.2%	73.2%	67.2%	66.7%
Hypertension Total number of adherent utilizers 2,658	75.2%	75.9%	75.1%	73.9%
Hyperlipidemia Total number of adherent utilizers 1,606	78.4%	78.5%	76.0%	75.3%
Heart Failure Total number of adherent utilizers 318	53.3%	51.3%	55.5%	55.4%
Depression Total number of adherent utilizers 2,711	65.6%	66.4%	67.0%	65.9%


¹ Optimal: ≥ 80% MPR

*Peer: Government

**Age-adjusted benchmarks represent the optimal adherence % of the book of business segment and peer based on the same age demographics as the client.

Managing chronic conditions: your adherence measures

Percent optimal¹ adherence by chronic condition



¹ Optimal: ≥ 80% MPR

*Peer: Government


**Age-adjusted benchmarks represent the optimal adherence % of the book of business segment and peer based on the same age demographics as the client.

Membership change affecting cost


Member metrics

	Members that	Members Remaining Eligible in The Plan		Members
	Left The Plan	Jul-May 22	% Change	New to The Plan
Distinct Eligible Members	5,900	30,169	0.0%	8,408
Average Eligible Members	2,844	27,627	-0.2%	5,163
Average Member Age	36	35	2.9%	32
Percent Utilizing Members	31.0%	29.6%	2.8%	23.5%
Gross Cost Per Member Per Month (PMPM)	\$136.31	\$123.00	16.7%	\$92.50
Net Cost Per Member Per Month (PMPM)	\$126.39	\$113.60	17.5%	\$84.59
Days' Supply Per Member Per Month (PMPM)	28.17	25.65	6.7%	18.99
Rx PMPM	0.70	0.62	4.5%	0.50
Gross Cost Per Utilizer Per Month (PUMPM)	\$439.54	\$415.83	13.5%	\$393.09
Net Cost Per Utilizer Per Month (PUMPM)	\$407.55	\$384.06	14.3%	\$359.47
Days' Supply Per Utilizer Per Month (PUMPM)	91	87	3.8%	81
Rx PUPM	2.26	2.09	1.7%	2.12


Jul 2021-May 2022 Cost Comparison




Jul 2022-May 2023 Cost Comparison



Jul 2021-May 2022 Utilization Comparison



Jul 2022-May 2023 Utilization Comparison



Projected savings from new generics

Generic outlook

Projected savings from Jun 2023 - May 2024 generic launches*

Rank	Drug Name	Utilizers	Total Rxs	Jun-May 24	Jun-May 25	Jun-May 26	Total
1	Vyvanse	251	1,203	\$199,575	\$513,381	\$569,222	\$1,282,177
2	Spiriva	13	57	\$19,858	\$40,941	\$42,918	\$103,716
3	Forteo	1	11	\$20,881	\$37,060	\$39,093	\$97,033
4	Isentress	1	3	\$1,251	\$18,029	\$24,297	\$43,577
5	Livalo	3	14	\$1,995	\$8,282	\$8,815	\$19,091
6	All Other	10	23	\$3,891	\$11,855	\$13,163	\$28,909
	Total	279	1,311	\$247,450	\$629,548	\$697,506	\$1,574,504

Projected savings from Jun 2024 - May 2025 generic launches*

Rank	Drug Name	Utilizers	Total Rxs	Jun-May 25	Jun-May 26	Total
1	Sprycel	2	18	\$78,931	\$245,394	\$324,325
2	Victoza	40	146	\$104,917	\$192,057	\$296,974
3	Brilinta	1	4	\$540	\$14,482	\$15,022
4	N/A	0	0	\$0	\$0	\$0
5	N/A	0	0	\$0	\$0	\$0
6	N/A	0	0	\$0	\$0	\$0
	Total	43	168	\$184,388	\$451,933	\$636,321

*Impact of future generic launches has been calculated by drug strength and rolled up by drug name. GDR impact and savings are reported under brand name and launch date of the first available generic within each drug name. This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or its affiliates.

Your top 5 retail pharmacy chains

By gross cost

Retail Pharmacy Chain	Total Rxs	Utilizers	Gross Cost	Rx PMPM	% of Total Rxs	% of Utilizers
DILLONS-KROGER CENTRAL	51,661	7,882	\$5,149,778	0.14	24.7%	32.0%
WALMART	29,656	3,952	\$3,118,645	0.08	14.2%	16.0%
WALGREENS CORPORATION	35,025	6,087	\$3,036,288	0.10	16.8%	24.7%
CVS PHARMACY INC	18,140	2,866	\$1,870,452	0.05	8.7%	11.6%
SAFEWAY INC - DENVER DIVISON	16,117	2,456	\$1,509,874	0.04	7.7%	10.0%
Subtotal for Top 5 Retail Chains	150,599	19,911	\$14,685,037	0.42	72.1%	80.7%
All Other Retail Chains	58,409	4,751	\$5,291,869	0.16	27.9%	19.3%
Total Retail	209,008	24,662	\$19,976,905	0.58	100.0%	100.0%

Pharmacogenomic Testing in Precision Medicine

Using evidence-based
testing to improve outcomes,
lower costs

May 2023




What is Pharmacogenomics (PGx)?

Provides an opportunity to help **personalize drug therapy**, increasing the likelihood of drug efficacy and safety

Addresses drug response variability which is influenced by factors such as age, gender, weight, disease state and race

Helps identify responders and non-responders to medications, avoiding adverse events and optimizing drug dose

The goal is for evidence-based testing to improve outcomes, lower costs



Examples of where testing has demonstrated value

Specialty medication	Mutation being tested	Lab or genetic testing	Documentation required
Mekinist	BRAF V600, BRAF V600E, BRAF V600K	BRAF mutation testing	BRAF mutation status
Trikafta	CFTR gene mutation	CFTR genetic testing	Genetic testing showing the presence of an appropriate CFTR gene mutation



~200

SGM programs
require genetic tests

Why aren't we there yet?

Outside drug labeling, PGx has proposed uses that have not materialized

Mental health, anticoagulation and polypharmacy have been areas of promise

Large, high-quality studies have repeatedly **failed to produce outcomes** relevant enough to warrant the intervention

Actionable PGx drug-gene pairs are **not always feasible** or cost-effective

Low consensus between guideline-publishing entities

Different coverage among Medicare, Medicaid and commercial payors



We continuously monitor the science and economics to identify testing modalities that bring value to our clients and put members on their path to better health

Legal disclaimers

The source for data in this presentation is CVS Health Enterprise Analytics unless otherwise noted.

All data sharing complies with applicable law, our information firewall and any applicable contractual limitations.

Adherence and health outcome results, savings projections and performance ratings are based on CVS Caremark data. Actual results may vary depending on benefit plan design, member demographics, programs implemented by the plan and other factors. Client-specific modeling available upon request.

The Maintenance Choice program is available to self-funded employer clients that are subject to ERISA. Non-ERISA plans such as fully insured health plans, plans for city, state or government employees and church plans need CVS Caremark legal approval prior to adopting the Maintenance Choice program. Prices may vary between mail service and CVS Pharmacy due to dispensing factors, such as applicable local or use taxes.

Specialty Expedite is available exclusively for providers who use compatible electronic health record (EHR) systems, including Epic Systems and others that participate in the Carequality Interoperability Framework.

Specialty delivery options are available where allowed by law. In-store pick up is currently not available in Oklahoma. Puerto Rico requires first-fill prescriptions to be transmitted directly to the dispensing specialty pharmacy. Products are dispensed by CVS Specialty and certain services are only accessed by calling CVS Specialty directly. Certain specialty medication may not qualify. Services are also available at Long's Drugs locations.

Patient stories and patient names are presented for illustrative purposes only. Any resemblance to an actual individual is coincidental. Unless otherwise specified, images contained within are licensed or the property of CVS Health or one of its affiliates.

This presentation contains trademarks or registered trademarks of CVS Pharmacy, Inc. or one of its affiliates; it may also contain references to products that are trademarks or registered trademarks of entities not affiliated with CVS Health.

Glossary

Glossary of terms

Acute Medication

A prescription drug typically taken for a short period of time, usually a 30-day supply filled at a retail pharmacy.

Adherence—MPR

Medication Possession Ratio (MPR) is the ratio of actual day's supply dispensed to the potential days of use from an initial fill date until the end of the reporting period. Disease state MPR is a weighted average of specific therapeutic class MPR.

Adherence—Optimal

Individuals with Medication Possession Ratio (MPR) or Proportion Days Covered (PDC) of 80% or above during the reporting period.

Adherence—PDC

Proportion Days Covered (PDC) is an alternative way to measure adherence and is used by the Center for Medicare and Medicaid (CMS). PDC is calculated based on fill dates and days supply, but it looks at the number of days between the first fill during the measurement period and the end of the measurement period. Used for Medicare and Exchange clients.

Age-Adjusted Peer

The age-adjusted peer benchmark provides Book of Business projected spend and utilization if the peer had the same age demographics as the client.

Average Wholesale Price (AWP)

Average wholesale price for a prescription drug from the most current pricing information provided by First DataBank, Medi-Span Prescription Pricing Guide (with supplements) or any other nationally available reporting service of pharmaceutical data.

Book of Business (BOB)

This is published data that demonstrates at company level how the various major product lines of the company are performing on different parameters such as adherence and persistency.

Dual Therapy

Patients that are receiving oral as well as injectable drugs for this therapy.

Exclusive Specialty Pharmacy Network

This program consolidates access to specialty medications solely through CVS Caremark Specialty Pharmacy.

FDA

U.S. Food and Drug Administration

FSA

Flexible Spending Account

Generic Dispensing Rate (GDR)

The percent of all payable prescriptions that were dispensed as generic drugs.

Gross Cost

Client total cost plus member cost.

Maintenance Medication

A prescription drug typically taken on a regular basis to treat a chronic condition, usually a 90-day supply filled at mail or retail pharmacy.

Medical Carve Out

Identification of specialty drugs billed/paid under the medical benefit that could be transitioned to the pharmacy benefit to help ensure high quality clinical management, to decrease costs and increase data transparency.

MinuteClinic[®]

These are retail-based clinics staffing nurse practitioners and physician assistants treating a limited number of common ailments and offering routine vaccinations. MinuteClinic offers a convenient and cost-friendly option for treatment of certain minor illnesses.

Miscellaneous Drugs

Items classified as "Miscellaneous" are: Products that CVS Caremark dispenses as ancillary medications used for the administration of medication; products dispensed to a utilizing member, per their request, because of the convenience of getting drugs from one site; a single drug in a class/category and/or for a therapy that fits in with other therapies the utilizing member is receiving for a condition.

Glossary of terms (continued)

MSB/SSB

Multi Source Brand/Single Source Brand

Net Cost

Client total amount paid

Non-CVS/specialty

All other pharmacies (traditional, retail or other specialty) other than CVS Caremark Specialty Pharmacies.

Normalized AWP

The CVS Caremark RxInsights® Report normalizes the AWP amount. Given AWP is a calculated field, it relies on the quality of both the quantity dispensed and the AWP price. There are instances where the quantity dispensed does not match with the unit cost which may potentially lead to incorrect amounts. This frequently occurs with compound claims, creams, powders, injectables, etc.

Onboarded

Contacted/engaged by a Care Team (either telephonically or with a "Getting Started" direct mail kit

Over-the-Counter (OTC)

over-the-counter

PEPM/PEPY

Per Employee Per Month/Per Employee Per Year

PMPM/PMPY

Per Member Per Month/Per Member

Prevalence

Used to measure the proportion of population that has a specific condition at some time during the reporting period.

PUMPM/PUMPY

Per Utilizing Member Per Month/Per Utilizing Member Per Year

Site of Care Alignment

Analysis of combined medication cost and administration cost to identify circumstances where a lower total costs could potentially be achieved by guiding the member to an alternative site of care or distribution channel

Specialty

Used to treat specific, low-incidence chronic and/or genetic conditions. These products are typically very expensive and may require member-specific dosing, medical devices to administer the medication, and/or special handling and delivery.

Specialty Connect

The integration of our retail and specialty mail pharmacy capabilities. It expands access and convenience to 7,500 CVS Pharmacy locations. Patients can drop off or pick up their specialty prescriptions at a CVS Pharmacy, but the dispensing, drug utilization review and clinical management occurs at our specialty pharmacy.

Specialty Preferred Drug Strategies

Preferred drug list, step therapy and closed formulary strategies encourage utilization of clinically appropriate and lowest net cost medications within select therapeutic categories. These programs positively influence member and prescriber behavior to help reduce cost without compromising quality of care.

Specialty Guideline Management (SGM)

A program that helps ensure appropriate utilization for specialty medications based on evidence-based medicine guidelines and consensus statements. Utilizing member progress is continually assessed to determine whether appropriate therapeutic results are achieved. Standard criteria is available for most specialty drug classes with the ability to implement client-specific criteria.

Trend Components

Provides a breakdown of the independent drivers of gross/net trend. These components have a multiplicative, not additive, relationship with respect to non-biotech gross/net trend. Components of trend include price (average cost per unit), utilization (days' supply PMPY) and product mix (includes new products, changes to the blend of brand and generic drugs, and intensity).

Top therapeutic class description: drug classes, conditions and drug examples

ADHD/Antinarcology/Antiobesity Agents

ADHD, Narcolepsy, Obesity
Amphetamine/dextroamphetamine, Focalin XR, Intuniv, Vyvanse, Modafinil, Nuvigil, phentermine, Belvii, Qsymia

Analgesic Anti-inflammatory

Pain and Inflammation, Rheumatoid Arthritis
Ibuprofen, Meloxicam, Naproxen, Diclofenac, Nabumetone, Celebrex, Naprelan, Leflunomide, Enbrel, Humira, Xeljanz

Analgesic Opioid

Pain
Hydrocodone-Acetaminophen, Tramadol, Oxycodone, Oxycodone-Acetaminophen, Fentanyl, Morphine, Nucynta, Suboxone, Subsys

Antiasthmatic and Bronchodilator Agents

Asthma, COPD
Montelukast, Albuterol, Levalbuterol, Budesonide, Advair, Spiriva, Symbicort, Combivent, Dulera, Xolair

Anticonvulsant

Epilepsy, Nerve Pain
Gabapentin, Topiramate, Lamotrigine, Levetiracetam, Divalproex, Oxcarbazepine, Clonazepam, Lyrica, Onfi

Antidepressant

Depression, Anxiety Disorders
Escitalopram, Sertraline, Fluoxetine, Paroxetine, Venlafaxine, Trazodone, Cymbalta, Pristiq, Viibyrd

This is not an all inclusive list.

This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

Antidiabetic

Diabetes
Metformin, Glimepiride, Glipizide, Glyburide, Pioglitazone, Lantus, Novolog, Victoza, Byetta, Januvia, Tradjenta

Antihyperlipidemic

High Cholesterol
Atorvastatin, Simvastatin, Livalo, Crestor, Advicor, Simcor, Vytorin, Zetia, Welchol, Niaspan, Lovaza, Vascepa

Antihypertensive

High Blood Pressure
Lisinopril/HCT, Losartan/HCT, Olmesartan/HCT, Valsartan/HCT, Amlodipine-Benazepril, Enalapril, Ramipril, Exforge, Azor, Tekturna, Tarka

Antipsychotic

Bipolar Disorder, Schizophrenia
Olanzapine, Quetiapine, Risperidone, Ziprasidone, Abilify, Geodon, Latuda, Lithium, Haloperidol, Clozapine

Antivirals

HIV/AIDS, Hepatitis C, Herpes, Influenza
Lamivudine, Atripla, Truvada, Isentress, Complera, Stribild, Incivek, Victrelis, Pegasys, Valacyclovir, Tamiflu

Dermatologicals

Acne, Psoriasis, Various Skin Conditions
Adapalene, Triamcinolone acetate, Clindamycin phosphate, Lidoderm, Aldara, Oracea, Epiduo, Stelara

Endocrine and Metabolic

Osteoporosis, Growth Hormone, Infertility
Alendronate, Ibandronate, Actonel, Evista, Forteo, Norditropin, Clomiphene, Follistim, Sensipar, Samsca

Hematologicals

Prevention of Blood Clots, Prevention of Heart Attacks and Stroke, Hemophilia
Clopidogrel, Cilostazol, Dipyridamole, Ticlopidine, Aggrenox, Effient, Brilinta, Advate, Humate-P

Oncology Agents

Breast Cancer, Colorectal Cancer
Gleevec, Xeloda, Temodar, Sprycel, Tarceva, Sutent, Afinitor, Rituxan, Xalkori, Jakafi, Votrient, Inlyta

Psychotherapeutic and Neurological Agents

Alzheimer's Disease, Multiple Sclerosis, Smoking Cessation
Donepezil, Rivastigmine, Exelon patch, Namenda, Horizant, Chantix, Copaxone, Avonex, Gilenya, Aubagio

Ulcer Drugs

Acid Reflux, Ulcers, Heartburn
Omeprazole, Lansoprazole, Pantoprazole, Ranitidine, Famotidine, Cimetidine, Aciphex, Nexium, Dexilant

Specialty drug classes drug class ID,

AAT (Alpha-1 Antitrypsin Deficiency)

Aralast, Glassia, Prolastin, Zemara

ACROMEGALY (Acromegaly)

Octreotide, Octreotide Acetate, Sandostatin, Signifor Lar, Somatuline, Somavert Depot, Somavert

ALCOHOLISM (Alcohol Dependency)

Probuphine Implant Kit, Vivitrol

ALLERGN (Allergen Immunotherapy)

Oralair

ANEMIA (Anemia)

Aranesp, Epogen, Mircera, Omontys, Procrit, Cinqair, Nucala

ASTHMA (Asthma)

Xolair

BOTULINUMS (Botulinums Toxins)

Botox, Dysport, Myobloc, Xeomin

CAPS (Cryopyrin Associated Periodic Syndromes)

Arcalyst, Ilaris

CARDIAC (Cardiac Disorders)

Dofetilide, Tikosyn

CF (Cystic Fibrosis)

Bethkis, Cayston, Kalydeco, Kitabis Pak, Orkambi, Pulmozyme, Tobi, Tobi Podhaler, Tobramycin

COAGUL (Coagulation Disorders)

Ceproin

CONTRACEPT (Contraceptives)

Implanon, Klyeena, Liletta, Mirena, Nexplanon, Skyla

CRSwNP (Chronic Rhinosinusitis with Nasal Polyps)

Dupixent

CUSHING'S SYNDROME (Cushing's Syndrome)

Korlym, Signifor

DUPUYTREN (Dupuytren's Contracture)

Xiaflex

ELECTROLYT (Electrolyte Disorders)

Keveyis, Samsca, Veltassa

GI OTHER (Gastrointestinal Disorders-Other)

Cholbam, Gattex, Ocaliva, Solesta

GOUT (Gout)

Krystexxa

HAE (Hereditary Angioedema)

Cinryze, Berinert, Firazyf, Kalbitor

HEMATO (Hematopoietics)

Mozobil, Neumega, Prokine

HEMO (Hemophilia)

Advate, Adynovate, Afstyla, Alphanate, Aphanine, Alprolix, Autoplex T, Bebulin, BeneFIX, Bioclote, Coagadex, Corifact, Eloctate, Factor VIII, Feiba, Genarc, Helixate, Hemofil-M, HT Factor, Humate-P, Idelvion, Ixinity, Koate, Kogenate, Kogenate FS, Konyne 80, Kovaltry, Melate, Monarc-M, Monoclate, MonoNine, NovoEight, NovoSeven, Nuwiq, Profi OSD, Profilate, Profilnine, Proplex T, Recombinate, Refacto, RiaSTAP, Rixubis, Stimate, Tretten, Vonvendii, Wilate, Xyntha

HEPB (Hepatitis B)

Adefovir Dipivoxil, Baraclude, Entecavir, Epivir HBV, Hepsera, Lamivudine, Tyzeka, Vemlidy

HEPC (Hepatitis C)

Corpegus, Daklinza, Eplclusa, Harvoni, Incivek, Infergen, Moderiba, Olysio, Peg-Intron, Pegasys, Rebetal, Ribapak, Ribasphere, Ribavirin, Sovaldi, Technivie, Victrelis, Viekira, Zepatier

HGH (Growth Hormone and Related Disorders)

Genotropin, Humatrope, Increlex, Norditropin, Nutropin, Omnitrope, Protropin, Saizen, Serostim, Tev-Tropin, Zormacton, Zorbtive

HIV (Human Immunodeficiency Virus)

Injectable: Egrifta, Fuseon

Oral: Agenerase, Aptivus, Atripla, Combivir, Complera, Crixivan, Didanosine (Videx), Edurant, Epivir, Epzicom, Intelence, Kaletra, Lexiva, Norvir, Prezista, Rescriptor, Reyataz, Selzentry, Stavudine (Zerit), Stribild, Sustiva, Trizivir, Truvada, Videx, Viracept, Viread, Ziagen, Zidovudine (Retrovir)

HORM (Hormonal Therapies)

Aveed, Eligard, Firmagon, Leuprolide Acetate, Lupaneta Pack, Lupron, Lupron Depot, Lupron Depot-PED, Natpara, Repositort, Supprelin, Supprelin LA, Trelstar Depot, Trelstar LA, Trelstar Mixject, Vantas, Viadur, Zoladex

IBD (Inflammatory Bowel Disease)

Cimzia, Entyvio, Remicade, Stelara

IGIV (Immune Deficiencies and Related Disorders)

Carimune, Cytogam, Flebogamma, GamaSTAN S/D, Gamunex, Gammagard, Gammaked, Gammaplex, Hepagam B, Hizentra, HyperHEP B, HyperRHO S/D, Iveegam EN, MICRhoGAM, Nabi-HB, Octagam, Polygam S/D, Privigen, RhoGAM, Rhophylac, WinRho SDF

INFECTIOUS (Infectious Disease)

Actimmune, Alferon N

INFERTIL (Infertility)

Bravelle, Cetrotide, Chorionic Gonadotropin (Novarel, Pregnyl), Follistim AQ, Ganirelix Acetate, Gonal-F, Luveris, Menopur, Ovidrel, Repronex

IRON OVERL (Iron Overload)

Deferoxamine, Desferal, Exjade, Ferriprox

ITP (Immune (Idiopathic) Thrombocytopenic Purpura)

Nplate, Promacta

LIPID (Lipid Disorders)

Juxtapid, Kynamro

LIPPCS (Lipid Disorders – PCSK9)

Praulent, Repatha

LIPODYSTROPHY

Myalept

Source: CVS Caremark Data Warehouse & Internal Sources

This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

*Drugs are classified according to their primary indication. This is not an all inclusive list

Specialty drug classes drug class ID,

LSD (Lysosomal Storage Disorder)

Adagen, Aldurazyme, Cerezyme, Cystagon, Elaprase, Eleyso, Fabrazyme, Myozyme, Naglazyme, VPRIV

MACDEG (Macular Degeneration)

Lucentis, Macugen, Visudyne

MIGRAINE

Zecuity

MISC (Miscellaneous)

Apligraf, Cystadane, Orfadin

MOVEMENT (Movement Disorders)

Apokyn, Xenazine

MS (Multiple Sclerosis)

Ampyra, Aubagio, Avonex, Betaseron, Copaxone, Extavia, Gilenya, Glatopa, Lemtrada, Mitoxantrone, Novantrone, Plegridy, Rebif, Tecfidera, Tysabri, Zinbryta

NEUTROPENIA (Neutropenia)

Leukine, Neulasta, Neupogen

NRAXSPA (Non-Radiographic Axial Spondyloarthritis)

Cimzia Prefilled Syringe, Cosentyx

ONCOL (Oncology)

Injectable: Arzerra, Avastin, Dacogen, Elspar, Erbitux, Erwinaze, Folutyn, Fusilev, Halaven, Herceptin, Intron A, Istodax, Ixempra, Jevtana, mitoxantrone (Novantrone), Oncaspar, Proleukin, Rituxan, Roferan-A, Synribo, Temodar, Thyrogen, Torisel, Treanda, Velstar, Vectibix, Velcade, Xgeva, Zometa and numerous others
Oral/Topical: Afinitor, Bosulif, Cometriq, Eylea, Gleevec, Hycamtin, Iclusig, Jakafi, Nexavar, Revlimid, Sprycel, Stivarga, Sutent, Tarceva, Targretin, Tassigna, Temodar, Thalomid, Tykerb, Votrient, Xalkori, Xeloda, Zelboraf, Zolanza, Zytiga

OSTEOA (Osteoarthritis)

Euflexxa, Hyalgan, Orthovisc, Supartz, Synvisc, Synvisc One

OSTEOP (Osteoporosis)

Forteo Prolia, Reclast

PAH (Pulmonary Arterial Hypertension)

Adcirca, Adempas, Epoprostenol, Flolan, Letairis, Opsumit, Orenitram, Remodulin, Revatio, Sildenafil Citrate, Tracleer, Tyvaso, Upravi, Veletri, Ventavis

PAIN MANAG (Pain Management)

Prialt

PKU (Phenylketonuria)

Kuvan

PNH (Paroxysmal Nocturnal Hemoglobinuria)

Soliris

PSOR (Psoriasis)

Amevive, Cosentyx, Otezla, Raptiva, Stelara, Taltz

P-T BIRTH (Pre-Term Birth)

Makena

PULMOTH (Pulmonary Disorders – Other)

Esbriet, Ofev

RA (Rheumatoid Arthritis)

Actemra, Enbrel*, Humira*, Inflectra, Kineret, Orenzia, Otrexup, Rasuvo, Remicade*, Simponi, Xeljanz

RENAL (Renal Disease)

Sensipar

RETINAL (Retinal Disorders)

Iluvien, Jetrea, Ozurdex, Retisert

RSV (Respiratory Syncytial Virus)

Synagis

SEIZURE (Seizure Disorders)

H.P. Acthar Gel, Sabril

SLE (Systemic Lupus Erythematosus)

Benlysta

SLEEP (Sleep Disorder)

Hettioz

TRANSPLT (Transplant)

Cellcept, Cyclosporine (Gengraf, Neoral, Sandimmune), Mycophenolate Mofetil (Cellcept), Myfortic, Rapamune, Tacrolimus (Prograf), Zortress

UREA (Urea Cycle Disorders)

Carbaglu

VENOUS INSUFFICIENCY

Varithena

Source: CVS Caremark Data Warehouse & Internal Sources

This page contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS

*Drugs are classified according to their primary indication. This is not an all inclusive list

